Publications

Cracks through the ice on a melting glacier in Alaska

A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold

1 July 2020

This paper presents a supply and demand model of pharmaceutical markets to analyse the relationship between the value of the Cost-Effectiveness Threshold (CET) and the distribution…

How Should the World Pay for a COVID-19 Vaccine?

How Should the World Pay for a COVID-19 Vaccine?

1 July 2020

This year’s OHE lecture addresses the question: how should the world pay for a COVID-19 vaccine? Adrian Towse, Emeritus Director of OHE and Senior Research Fellow…

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

1 June 2020

In the 2017 Industrial Strategy, the Government committed to increasing investment in UK Research and Development to the OECD-average of 2.4% of Gross Domestic Product (GDP)…

Personalised Medicine: is it an Oil-Rush or Oil-Spill?

Personalised Medicine: is it an Oil-Rush or Oil-Spill?

1 May 2020

Personalised medicine, also known as ‘precision’ or ‘stratified’ medicine, targets treatment by using genetics and/or biomarkers to identify patients or subgroups of patients who have distinct…

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

5 January 2020

OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…

Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level

Closing the ‘Know-Do’ Gap for Health Systems Reform at the Policy Level

1 April 2020

The World Health Organisation (WHO) has become quite skilled at promoting what changes are desirable in health care systems, and why, but has largely left how…

Indication-Based Pricing (IBP) Consultation Report

Indication-Based Pricing (IBP) Consultation Report

1 April 2020

Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…

Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

Meningococcal Vaccines: An International Comparison of Decision-Making Processes, Frameworks and Methodologies. Are Values Missing?

3 January 2020

Meningococcal disease is a life-threatening infection and can result in severe sequelae. Recent scientific and technical advances have led to the discovery and implementation of novel…

The Evolution of US Policy Responses to the Opioid Epidemic

The Evolution of US Policy Responses to the Opioid Epidemic

1 March 2020

The ‘opioid epidemic’ in the US is the most recent drug-abuse challenge from the misuse of prescription medicines or the use of illicit drugs. It is…